Malevolent alliance of MYBL2hi cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer

Malevolent alliance of MYBL2hi cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer

Background Neoadjuvant immune checkpoint blockade (nICB) has revolutionized cancer treatment, yet the underlying mechanisms of resistance in bladder cancer remain to be explored.Methods We conducted single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells, tumor tissues, adjacent...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lin Ma, Jie Dong, Yingjie Li, Xuebin Zhang, Ziyi Li, Hualin Chen, Yi Xie, Zhaoheng Jin, Yueqiang Peng, Zhigang Ji
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-07-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/7/e011319.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Social Context of Malevolent Creativity
by: Harun Tadik, et al.
Published: (2025-05-01)

Neoadjuvant chemotherapy of invasive bladder cancer
by: S. N. Isayeva, et al.
Published: (2012-04-01)

Neoadjuvant chemotherapy for bladder cancer: Two decades on
by: Rishi Nayyar
Published: (2025-01-01)

Behavioral Features of Negative and Malevolent Creativity in Adolescents
by: Bochkova M.N., et al.
Published: (2019-05-01)

Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer
by: Jiao Hu, et al.
Published: (2025-08-01)

Malevolent Creativity of Adolescents in Different Socio-political Contexts
by: Natalya V. Meshkova, et al.
Published: (2024-12-01)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
by: Dalia Elsayed, et al.
Published: (2023-04-01)

Interrelation of Malevolent Creativity and Values in Adolescents with Different Levels of Aggression
by: Meshkova N.V.
Published: (2018-10-01)

Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer
by: Wei He, et al.
Published: (2025-07-01)

NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY IN THE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER
by: N. S. Nurgaliev, et al.
Published: (2016-10-01)

Effects of Neoadjuvant Chemotherapy on Rates of Depression in Muscle Invasive Bladder Cancer
by: Matthew DeSanto, et al.
Published: (2024-07-01)

Customer Relationship Malevolence: A Reflection on Accounting, Marketing and Customer Valuation
by: Kenneth Weir
Published: (2014-10-01)

Conference “(Hi)stories of American Women: Writings and Rewritings”
by: Élise Vallier
Published: (2013-02-01)

Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in muscle-invasive bladder cancer
by: Xinjia Ding, et al.
Published: (2025-05-01)

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
by: N. G. Cowan, et al.
Published: (2014-01-01)

Features of Malevolent Creativity and its Prevention in Adolescents in the Modern Socio-Political Context
by: N.V. Meshkova, et al.
Published: (2024-12-01)

Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer
by: Meritxell Pérez, et al.
Published: (2025-03-01)

Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
by: Shugo Yajima, et al.
Published: (2025-05-01)

Efficacy and immunological effects of neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer
by: GAO Zhiqiang, CHEN Tao, LIU Lei, SUN Chunshan, JI Yilong, TANG Hao
Published: (2025-04-01)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
by: Elizabeth A Guancial, et al.
Published: (2016-01-01)

Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
by: Victoria Gonzalez, et al.
Published: (2025-09-01)

Comparative efficacy of neoadjuvant therapy in the combined treatment of bladder cancer after open and transurethral resection
by: Y. V. Dumansky, et al.
Published: (2013-02-01)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
by: Hao Luo, et al.
Published: (2022-01-01)

Genome-wide identification of MYBL2 in Brassicaceae, with a focus on the expression pattern of regulating anthocyanin synthesis in Brassica crops
by: Chenchen Wang, et al.
Published: (2025-07-01)

Field dependent-independent cognitive style as a predictor of malevolent creativity: a multifaceted approach
by: Pierpaolo Zivi, et al.
Published: (2025-07-01)

The Connotation of "Dispelling Xiegui (Malevolent Pathogenic Influences)" in the Shennong's Classic of Materia Medica and the Study on Medication
by: Shujia YANG, et al.
Published: (2025-05-01)

Complete regress of a low-differentiated recurrence of the bladder cancer as the answer on two cycles of neoadjuvant polychemotherapy
by: P. G. Yakovlev, et al.
Published: (2020-05-01)

Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States
by: Caicong You, et al.
Published: (2025-07-01)

Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade
by: Sunny Goel, et al.
Published: (2019-07-01)

Citizens in democratic countries have more benevolent traits, fewer malevolent traits, and greater well-being
by: Craig S. Neumann, et al.
Published: (2025-04-01)

MYBL2 promotes cell proliferation and inhibits cell apoptosis via PI3K/AKT and BCL2/BAX/Cleaved-caspase-3 signaling pathway in gastric cancer cells
by: Jingya Chen, et al.
Published: (2025-03-01)

A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer
by: Chinna Babu Dracham, et al.
Published: (2022-07-01)

Muscle invasive bladder cancer treated with gemcitabine plus cisplatin as neoadjuvant chemotherapy during the second trimester of pregnancy
by: Takeshi Sasaki, et al.
Published: (2025-03-01)

A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy
by: Garrett K. Harada, MD, et al.
Published: (2025-01-01)

Comparative Efficacy of Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, and Neoadjuvant Chemo-Endocrine Therapy in Estrogen Receptor–Positive Breast Cancer Patients: A Meta-Analysis
by: Yi Yuan, et al.
Published: (2025-01-01)

Prediction of response to neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder cancer: role of immune-related gene expression
by: Hadeer Mahmoud, et al.
Published: (2025-07-01)

Spatial relationships and interactions of immune cell niches are linked to the pathologic response of muscle-invasive bladder cancer to neoadjuvant therapy
by: Wasilijiang Wahafu, et al.
Published: (2025-03-01)

FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
by: Yang Zhang, et al.
Published: (2022-03-01)

Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)

Neoadjuvant Treatment in Rectal Cancer
by: Srinath Bhradwaj R., et al.
Published: (2024-10-01)